Ignite Creation Date:
2024-05-05 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00419757
Status:
COMPLETED
Last Update Posted:
2012-08-27
First Post:
2007-01-05
Brief Title:
An Efficacy Study Comparing SYMBICORT Pressurised Metered Dose Inhaler pMDI With Budesonide Hydrofluoroalkanes HFA pMDI in Hispanic Subjects With ICS Dependent Asthma
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A 12-week Randomised Double Blind Active-controlled Multi-centre Phase IIIB Study Comparing the Efficacy and Safety of SYMBICORT pMDI 16045 mg x 2 Actuations Twice Daily Versus Budesonide HFA pMDI 160 mg x 2 Actuations Twice Daily in AdultAdolescent 12 Yrs Hispanic Subjects With Asthma
Status:
COMPLETED
Status Verified Date:
2012-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the effectiveness and safety of SYMBICORT pMDI a medication approved by the Food and Drug AdministrationFDA in the Hispanic population
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None